规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO |
|
||
1mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
体外研究 (In Vitro) |
使用针对 FAK Tyr-397 的抗磷酸特异性免疫印迹发现 PND-1186 在乳腺癌细胞中的 IC50 低于 100 nM [1]。 FAK 在小鼠 4T1 乳腺癌细胞中产生侵袭性和转移性细胞表型方面发挥着至关重要的作用。当 PND-1186 以不断增加的浓度(0.1 至 1.0 µM)引入 4T1 细胞时,FAK Tyr-397 磷酸化 (pY397) 会受到抑制,并且在一小时内,总 FAK 蛋白水平会升高[1]。
|
---|---|
体内研究 (In Vivo) |
当在颈部皮下注射(30 mg/kg 或 100 mg/kg)时,PND-1186 通过诱导细胞凋亡来抑制 4T1 皮下肿瘤的生长[1]。
|
细胞实验 |
蛋白质印迹分析[1]
细胞类型: 4T1 乳腺癌细胞 测试浓度: 0.1、0.2、0.4、0.6 和 1.0 µM 孵育时间:1小时 实验结果:抑制FAK Tyr-397磷酸化(pY397)并导致FAK总蛋白水平升高。 |
动物实验 |
Animal/Disease Models: balb/c (Bagg ALBino) mouse[1]
Doses: 30 mg /kg or 100 mg/kg Route of Administration: Injected (100 µL) subcutaneously (sc) in the neck region; every 12 h (twice-daily, bid) for 5 days. Experimental Results: 100 mg/kg treatment Dramatically decreased final 4T1 tumor weight 2-fold whereas 30 mg/kg treatment slightly decreased final tumor weight but was not Dramatically different compared to control. |
参考文献 |
[1]. Tanjoni I, et al. PND-1186 FAK inhibitor selectively promotes tumor cell apoptosis in three-dimensional environments. Cancer Biol Ther. 2010 May 15;9(10):764-77.
|
分子式 |
C25H26F3N5O3
|
---|---|
分子量 |
501.5
|
CAS号 |
1061353-68-1
|
相关CAS号 |
PND-1186 hydrochloride;1356154-94-3
|
SMILES |
O=C(NC)C1=CC=CC=C1NC2=CC(NC3=C(OC)C=C(N4CCOCC4)C=C3)=NC=C2C(F)(F)F
|
InChi Key |
IGUBBWJDMLCRIK-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C25H26F3N5O3/c1-29-24(34)17-5-3-4-6-19(17)31-21-14-23(30-15-18(21)25(26,27)28)32-20-8-7-16(13-22(20)35-2)33-9-11-36-12-10-33/h3-8,13-15H,9-12H2,1-2H3,(H,29,34)(H2,30,31,32)
|
化学名 |
2-((2-((2-methoxy-4-morpholinophenyl)amino)-5-(trifluoromethyl)pyridin-4-yl)amino)-N-methylbenzamide.
|
别名 |
SR-2156; VS-4718; PND-1186; PND 1186; PND1186; SR 2516; SR2516; VS4718; VS 4718.
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外) |
|
|||
---|---|---|---|---|
溶解度 (体内) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.99 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.99 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.99 mM) (saturation unknown) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 2% DMSO+30% PEG 300+5% Tween 80+ddH2O: 5mg/mL 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 1.9940 mL | 9.9701 mL | 19.9402 mL | |
5 mM | 0.3988 mL | 1.9940 mL | 3.9880 mL | |
10 mM | 0.1994 mL | 0.9970 mL | 1.9940 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
PND-1186 inhibitory effects differ from Dasatinib (Src inhibition). Cancer Biol Ther. 2010 May; 9(10): 764–777. td> |
PND-1186 inhibits ovarian carcinoma tumor growth. Cancer Biol Ther. 2010 May; 9(10): 764–777.Cancer Biol Ther.2010 May 15;9(10):764-77. td> |
Selective 4T1 cell apoptosis in suspension at low PND-1186 levels.Cancer Biol Ther.2010 May 15;9(10):764-77. td> |